Skip to main content
OpenTrials
Completed

NCT Number: NCT06632730

Therapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in Spain

An observational, retrospective, cross-sectional, multicenter study. Real-world data were obtained from medical records of Spanish public hospitals (9 hospitals).

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients diagnosed with SMA type I or SMA type II.
  • Patients with medical records available in the hospital.
  • Patients diagnosed with SMA type I or SMA type II after 2017 for whom a minimum of 6 months of follow-up was available.

Exclusion criteria

  • Patients who participated in an experimental design study except for those in the long-term follow-up period, during the observation period.

Treatment and study plan

Primary outcomes

  1. Cost per Year of Use of Resources for Medical Visits

    Time frame: Up to 12 months

    Medical visits included:

    • Primary care
    • Pediatric neurology
    • Rehabilitation physician
    • Traumatologist
    • Nutritionist
    • Pulmonologist
    • Cardiologist
    • Physical therapist
    • Nursing staff
    • Phoniatrist
    • Speech therapist
    • Rehabilitation sessions
    • Other specialists
    • Total medical visits
    • Hospital emergency room visits
    • Outpatient emergency room visit
    • Hospitalizations/Admissions to ward
    • Hospitalizations due to admissions to the intensive care unit (ICU)
    • Total hospitalizations (ward and ICU)
    • Therapy session separately from medical visits
  2. Costs per Year of Use of Resources for Medical Tests

    Time frame: Up to 12 months

    Medical tests included:

    • Blood count
    • Vitamin D test
    • Blood creatine kinase test
    • Electromyogram
    • Brain magnetic resonance imaging
    • Muscle magnetic resonance imaging
    • Bone densitometry
    • Nocturnal polysomnography
    • Muscle biopsy
    • Nerve conduction velocity study
    • Blood amino acid test
    • DNA test to confirm diagnosis
    • Total additional tests
  3. Cost per Year of Use of Resources for Treatment

    Time frame: Up to 12 months

    Treatments included:

    • Nusinersen (loading and maintenance dose)
    • Total Nusinersen
    • Risdiplam
    • Onasemnogene abeparvovec
    • Total treatments for SMA
    • Palivizumab
    • Influenza vaccine
    • Meningococcal vaccine
    • High protein shakes
    • Total adjuvant treatments
    • Total treatments

Secondary outcomes

  1. Number of Patients per Sociodemographic Category

    Time frame: Baseline

    Sociodemographics included:

    • Biological sex
    • Dead patients
    • Growth percentiles for growth charts (3%, 4-15%, 16-50%, 51-85%, 86-97%, greater than 97%)
    • Patient's cohabitants (father, mother, both parents, brother(s), sister(s), other relatives)
    • Patient's caregiver (father, mother, both parents, brother(s), sister(s), other relatives)
    • Patient's primary caregiver (father, mother, both parents, brother(s), sister(s), other relatives)
  2. Sociodemographic: Age

    Time frame: Baseline

    • Age at the time of data collection
    • Age of onset of SMA symptoms
    • Age at clinical diagnosis of SMA
    • Age of death
  3. Sociodemographic: Weight

    Time frame: Baseline

  4. Sociodemographic: Height

    Time frame: Baseline

  5. Sociodemographic: Body mass index (BMI)

    Time frame: Baseline

  6. Number of Patients per Clinical Characteristic Category

    Time frame: Baseline

    Clinical characteristics included:

    • Anti-adeno-associated virus serotype 9 (AAV9) antibody titer test
    • Neonatal screening for SMA together with other screening tests
    • Prenatal or perinatal SMA diagnosis
    • Ventilatory support
    • Patient with scoliosis
    • Patient with scoliosis surgery
    • Patients with a chair for scoliosis
    • Total or partial cost of the chair for scoliosis borne by the family
    • Patients still use a chair for scoliosis at the time of data collection
    • Patients with back brace
    • Total or partial cost of the back brace borne by the family
    • Patient with hip dislocations or subluxations
    • Head control
    • Relevant medical record
    • End of ventilatory support
  7. Clinical Characteristic: Age From Which Information Was Available

    Time frame: Baseline

  8. Clinical Characteristic: Time From Onset of Symptoms to Diagnosis

    Time frame: Baseline

    Time intervals included:

    • Less than 1 month
    • 1 to 3 months
    • 4 to 6 months
    • 7 to 18 months
    • More than 18 months
  9. Clinical Characteristic: Number of Patients Categorized by International Classification of Diseases (ICD) Code

    Time frame: Baseline

    ICD codes included:

    • ICD-9 335.1: Spinal muscular atrophy
    • ICD-9: 335.1: Spinal muscular amyotrophy, unspecified
    • ICD-9 335.11: Kugelberg-Welander disease
    • ICD-10 G12.1: Other hereditary spinal muscular atrophies
    • ICD-10 G12.25: Progressive spinal muscular atrophy
    • ICD-10 G12.8: Other spinal muscular atrophies and related syndromes
    • ICD-10 G12.9: Spinal muscular atrophy, unspecified
  10. Clinical Characteristic: Number of Patients Categorized by Type of Diagnosis of Muscle Atrophy

    Time frame: Baseline

    Diagnosis types included:

    • Clinical suspicion and subsequent patient referral for genetic confirmation
    • Genetic diagnosis
  11. Clinical Characteristic: Number of Patients Categorized by Type of Mutation

    Time frame: Baseline

    Mutations included:

    • Biallelic deletion of exons
    • Biallelic deletion of exon 7
    • Biallelic deletion of exons 7 and 8
    • Compound heterozygous mutation
    • Point mutation and deletion of exons 7 and 8
    • Biallelic point mutation
  12. Clinical Characteristic: Number of Patients Categorized by Survival of Motor Neuron 2 (SMN2) Gene Copy Number

    Time frame: Baseline

    SMN2 copy numbers: 0, 1, 2, 3, 4, and greater than 4.

  13. Clinical Characteristic: Number of Patients Categorized by SMA-associated Comorbidities

    Time frame: Baseline

    SMA-associated comorbidities included:

    • Chronic lung disease
    • Swallowing impairment
    • Malnutrition
    • Hypoxic encephalopathy
    • Relapsing obstructive bronchial syndrome
    • Recurrent pneumonia
    • Sleep apnea-hypopnea syndrome
    • Epilepsy
    • Hip dysplasia
    • Obesity
    • Respiratory compromise
    • Thorax deformity
    • Scoliosis
    • Other
  14. Clinical Characteristic: Number of Patients Categorized by Family History of SMA

    Time frame: Baseline

    Family history categories included:

    • Yes
    • No
    • Mother
    • Father
    • Both parents
    • Brothers and sisters
    • Other
  15. Clinical Characteristic: Number of Patients Categorized by Type of Ventilatory Support

    Time frame: Baseline

    Types of ventilatory support included:

    • Invasive (hospital and outpatient)
    • Non-invasive (hospital and outpatient)
  16. Clinical Characteristic: Number of Patients Categorized by Reason of Ventilatory Support Regimen

    Time frame: Baseline

    Reasons of ventilatory support included:

    • Preventive intent
    • Therapeutic intent
  17. Clinical Characteristic: Duration of Ventilatory Support

    Time frame: Baseline

  18. Clinical Characteristic: Number of Patients With Nutritional Supplementation

    Time frame: Baseline

  19. Clinical Characteristic: Number of Patients Categorized by Type of Administration of Nutritional Supplementation

    Time frame: Baseline

    Types of administration included:

    • By mouth
    • Through a feeding tube
    • Both (mouth and feeding tube)
    • Through gastrostomy
  20. Clinical Characteristic: Number of Patients Categorized by Type of Nutritional Supplementation Received by Mouth

    Time frame: Baseline

    Types of nutritional supplementation included liquid thickeners (corn starch and Nutilis Clear thickener, neutral taste, Nutricia) and nutrition supplements (Resource shakes, High protein shakes, Ensure Junior drink, Infatrini, Pediasure Complete, RESOURCE C, Vitamin D, Fortini high protein shakes, protein shakes, Pediasure, Resource with fiber, Resource protein).

  21. Clinical Characteristic: Number of Patients Who Received Liquid Thickener and Nutritional Supplements by Mouth

    Time frame: Baseline

  22. Clinical Characteristic: Number of Patients Who Received Liquid Thickener and Nutritional Supplements Through a Feeding Tube

    Time frame: Baseline

  23. Clinical Characteristic: Duration of Nutritional Supplementation Received by Mouth and Through a Feeding Tube or Gastrostomy

    Time frame: Baseline

  24. Clinical Characteristic: Number of Surgeries for Patients With Scoliosis

    Time frame: Baseline

  25. Clinical Characteristic: Number of Patients Categorized by Type of Surgery Received for Scoliosis

    Time frame: Baseline

    Types of surgeries included:

    • Growing rods lengthening
    • Dorsal/lumbar dorsal arthrodesis
    • Growing rods
  26. Clinical Characteristic: Number of Patients Categorized by Type of Joint Contracture

    Time frame: Baseline

    Types of joint contractures included proximal and distal.

  27. Clinical Characteristic: Number of Patients Who Reached Each Motor Development Milestone

    Time frame: Baseline

    Developmental Milestones:

    • Sitting independently or with support
    • Standing independently or with support
    • Walking independently or with support
    • Crawling with the elbows, belly crawl, or with hands and knees
  28. Clinical Characteristic: Number of Patients Categorized by Relevant Surgical History in Addition to Scoliosis Surgery Related to SMA Categorized by Type of Surgery

    Time frame: Baseline

    Surgeries included:

    • Mouth surgery
    • Tracheostomy
    • Surgery for gastrostomy
    • Tenotomy
    • Other
  29. Number of Scheduled and Unscheduled Healthcare Visits per Patient per Year

    Time frame: Up to 12 months

    Healthcare visits included:

    • General
    • Primary care
    • Pediatric neurology
    • Rehabilitation physician
    • Traumatologist
    • Nutritionist
    • Pulmonology
    • Cardiologist
    • Physical therapy
    • Nursing staff
    • Phoniatrist
    • Speech therapist
    • Rehabilitation sessions
    • Other experts
    • Emergency Room
    • Related to therapy
  30. Total Number of Scheduled and Unscheduled Healthcare Visits per Patient per Year

    Time frame: Up to 12 months

  31. Number of Scheduled and Unscheduled SMA-related Medical Visits

    Time frame: Up to 12 months

    SMA-related medical visits included:

    • Primary care
    • Pediatric neurology
    • Rehabilitation physician
    • Traumatologist
    • Nutritionist
    • Pulmonologist
    • Cardiologist
    • Physical therapist
    • Nursing staff
    • Phoniatrist
    • Speech therapist
    • Rehabilitation sessions
    • Other specialists
  32. Number of SMA-related Emergency Room Visits

    Time frame: Up to 12 months

    SMA-related emergency room visits included outpatient and hospital visits.

  33. Number of SMA-related Hospitalizations

    Time frame: Up to 12 months

    SMA-related hospitalizations included visits to day hospital, admissions to ward, intensive care unit admissions.

  34. Number of Patients Categorized by Reason for Hospitalization

    Time frame: Up to 12 months

    Hospitalization included admission to ward. Reason for hospitalization included related to treatment and not related to treatment.

  35. Number of Patients Categorized by Reason for Admission to Intensive Care Unit (ICU)

    Time frame: Up to 12 months

    Reason for admission to ICU included related to treatment and not related to treatment.

  36. Number of Patients With a Multidisciplinary Follow-up

    Time frame: Up to 12 months

  37. Number of Patients Categorized by Medical Areas Involved in Follow-up

    Time frame: Up to 12 months

    Medical areas included:

    • Pulmonology
    • Endocrinology/nutrition
    • Physical therapy
    • Rehabilitation
    • Logopedics
    • Thoracic surgery
    • Orthopedics
    • Other
  38. Number of Patients Categorized by Type of Additional Tests Needed

    Time frame: Up to 12 months

    Additional tests included:

    • Blood count
    • Vitamin D test
    • Blood creatine kinase test
    • Electromyogram
    • Brain magnetic resonance imaging
    • Muscle magnetic resonance imaging
    • Bone densitometry
    • Nocturnal polysomnography
    • Muscle biopsy
    • Nerve conduction velocity study
    • Blood amino acid test
    • DNA test to confirm diagnosis
  39. Number of Times Each Additional Test Was Performed

    Time frame: Up to 12 months

    Additional tests included:

    • Blood count
    • Vitamin D
    • Blood creatine kinase
    • Electromyogram
    • Brain magnetic resonance imaging
    • Muscle magnetic resonance imaging
    • Bone densitometry
    • Nocturnal polysomnography
    • Muscle biopsy
    • Nerve conduction velocity study
    • Blood amino acid test
    • DNA test to confirm diagnosis
  40. Total Additional Tests

    Time frame: Up to 12 months

  41. Number of Patients Categorized by Type of Treatment for SMA

    Time frame: Up to 6 years and 4 months

    Treatments included:

    • Nusinersen
    • Risdiplam
    • Onasemnogene abeparvovec
    • Palivizumab
    • Influenza vaccine
    • Meningococcal vaccine
    • High protein shakes
  42. Number of Nusinersen Doses

    Time frame: Up to 6 years and 4 months

    Nusinersen doses included loading and maintenance doses.

  43. Risdiplam Dose

    Time frame: Up to 6 years and 4 months

    Risdiplam dose included starting dose and dose changes.

  44. Palivizumab Dose

    Time frame: Up to 6 years and 4 months

  45. Number of High Protein Shakes per Day

    Time frame: Up to 6 years and 4 months

  46. Number of Months of Taking High Protein Shakes

    Time frame: Up to 6 years and 4 months

Sponsors and collaborators

Lead sponsor

Novartis

Industry

Registry information

Official study title

Therapeutic Management and Current Situation Related to the Use of Resources and Costs of Spinal Muscular Atrophy (SMA) in Spain: A Retrospective, Multicenter Analysis Based on Medical Record Review. TREaSURE Study

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Oct 9, 2024
Registry last updated
Oct 9, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.